Aerie Pharmaceuticals, Inc. (AERI)

Trade AERI now with
5/15/2018 6:32:56 AM Aerie Pharmaceuticals Submits NDA To FDA For Roclatan (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
5/1/2018 6:31:35 AM Aerie Appoints Concetta Perro As Commercial Counsel
4/30/2018 6:32:26 AM Aerie Announces U.S. Launch Of Rhopressa (netarsudil Ophthalmic Solution) 0.02%
4/12/2018 6:35:02 AM Aerie Pharma Announces Appointment Of Scott Laranjo As Director, Marketing, Roclatan
2/20/2018 6:30:40 AM Aerie Pharmaceuticals Appoints John LaRocca As General Counsel
2/12/2018 6:32:14 AM Aerie Pharmaceuticals Appoints Scott Cassady As Regional Sales Director For The Central Region
2/8/2018 6:34:43 AM Aerie Pharma Appoints Brad Fuller As Director Of National Accounts In Its Market Access Department
2/1/2018 6:35:05 AM Aerie Pharmaceuticals Appoints Tad Heitmann As Head Of Communications
1/24/2018 6:31:01 AM Aerie Pharma Announces Pricing Of Public Offering Of Common Stock
1/23/2018 4:06:57 PM Aerie Pharma Announces Public Offering Of Common Stock
1/16/2018 6:31:50 AM Aerie Pharma Names Nils Hauptmann As Director Of Regulatory Affairs And Pharmacovigilance
1/7/2018 9:50:22 AM New Drugs Approved In December
1/2/2018 6:33:17 AM Aerie Pharma Appoints Julia Williams As Director Of Medical Affairs
12/1/2017 6:34:55 AM Aerie Pharmaceuticals Appoints Paul Bae As VP Of Human Resources
10/30/2017 6:31:36 AM Aerie Pharma Appoints John Maltman As VP Of Medical Affairs